ARTICLE | Clinical News

Exelixis jumps on XL184 data

November 19, 2010 2:00 AM UTC

Exelixis Inc. (NASDAQ:EXEL) gained $1.51 (32%) to $6.23 on Thursday after reporting interim data from 273 evaluable patients in the lead-in stage of an ongoing Phase II trial of XL184 to treat advanced solid tumors. Once-daily oral XL184 produced 39 partial responses and 100 cases of stable disease at week 12. The 12-week disease control rate (DCR) was 49%.

In 31 evaluable patients in the advanced epithelial ovarian cancer, primary peritoneal or fallopian tube carcinoma cohort, XL184 produced 10 confirmed partial responses, plus 15 cases of stable disease. The 12-week DCR was 64%. In 34 evaluable patients in the metastatic castration-resistant prostate cancer (CRPC) cohort, XL184 produced three confirmed partial responses, plus 25 cases of stable disease. The 12-week DCR was 71%. Data were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Berlin. As of Nov. 1, the trial had enrolled 397 of 600 patients with one of nine types of solid tumor. ...